|
(MoneyNewsWire.Net, September 25, 2016 ) "Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023". The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect.
Description-
Summary
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKlines (GSKs) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.
To Free Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=816336
Over the forecast period, the major driver of growth in the US HIV therapeutics market will be the launch of new drugs that offer improvements in terms of the pill burden, tolerability, and efficacy. Novel STRs will have the strongest positive impact on the market, and the drugs within this class of ART regimens include ViiVs recently launched INI-based STR, Triumeq, which was the first regimen to show superiority over Atripla.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Human Immunodeficiency Virus (HIV) market.
To Enquire Regarding This Report @ http://www.researchmoz.us/enquiry.php?type=E&repid=816336
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV).
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US
For More Information Kindly Contact:
ResearchMoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States
http://www.researchmoz.us,
Blog - http://bit.ly/2b1Ayn6
866-997-4948 (Us-Canada Toll Free),
+1-518-621-2074,
Email to: sales@researchmoz.us,
Researchmoz Global Pvt.Ltd
Researchmoz, Mr. Nachiket Ghumare
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
